The GLP-1R Agonist Semaglutide Reduces Motivated Running and Alters Dopamine Dynamics in the Nucleus Accumbens
Glucagon-like peptide-1 receptor (GLP-1R) agonists have recently emerged as powerful tools for the treatment of obesity through their ability to suppress food intake. However, their effects on non-ingestive motivated behaviors remain incompletely understood. Here, we show that the long-acting GLP-1R agonist semaglutide (SG) suppresses voluntary wheel running in both lean and diet-induced obese mice. Importantly, […]
GLP-1 drugs could save Uncle Sam billions — Congress should account for that
Obesity is a major public health and economic challenge in the US, costing the health care system an estimated $173 billion annually, and the Congressional Budget Office should refine its scoring methods to account for the long-term economic and societal costs of obesity and the efforts to mitigate it.
GLP-1 therapeutics may have the potential to treat alcohol and drug addiction
A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction, according to a new paper published in the Journal of the Endocrine Society.
ACS: 2020 to 2024 Saw Jump in Use of GLP-1 Receptor Agonists Before Metabolic, Bariatric Surgery
THURSDAY, Oct. 9, 2025 — The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) before surgery rose 16-fold among patients undergoing metabolic and bariatric surgery from 2020 to 2024, according to a study presented at the annual meeting…
Weight loss drug stigma shows society still holds negative attitudes towards body weight and obesity
Stigmatising the use of weight loss drugs is just a new form of ‘fatphobia.’ zimmytws/ Shutterstock Since Wegovy received approval as a weight loss treatment in 2021, there has been huge demand for GLP-1 drugs. These drugs reduce hunger and suppress the “food noise” that can make it difficult to lose weight. But while these […]
Noninvasive Tests May Track Semaglutide Response in MASH
Noninvasive tests show improvements in several relevant markers in patients with metabolic dysfunction-associated steatohepatitis treated with semaglutide for 72 weeks. Medscape Medical News
PepsiCo’s CEO says fiber will be the next protein
“Consumers are starting to understand that fiber is the benefit that they need,” Pepsi CEO Ramon Laguarta said. mladenbalinovac/Getty Images PepsiCo is ramping up its fiber offerings, expecting it to be “the next protein.” Companies have been packing food with protein, but health experts say fiber is often neglected. Increased dietary fiber is also recommended […]
Sam’s Club sells Ozempic, Wegovy
Sam’s Club pharmacies are now selling Novo Nordisk’s Ozempic and Wegovy for $499 per month, expanding consumer access to the popular GLP-1 drugs used for diabetes and weight loss. The retailer joins Costco, GoodRx and Novo Nordisk’s NovoCare Pharmacy in offering the same discounted price, according to an Oct. 8 report from USA Today. Wegovy’s […]
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?
Eli Lilly LLY and AbbVie ABBV are large, well-established U.S. pharmaceutical companies, boasting several blockbuster drugs, robust R&D pipelines, strong market capitalization and global footprint. Both companies have a strong presence in immunology, oncology and neuroscience areas. Other than that, AbbVie also has products for aesthetics and eye care, while Lilly boasts a leading presence in […]
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market
Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of more than $760 billion. It has been soaring in recent years due to the success of its highly effective GLP-1 products: Mounjaro for diabetes and Zepbound for weight loss. Whether it can continue rallying higher and potentially […]